UK-240455 is a potent and selective N-methyl-D-aspartic acid (NMDA) glycine receptor antagonist with neuroprotective effects and improved motor function in Parkinson's disease models, and is a potential candidate compound for treatment of Parkinson's disease.

After i.v. administration of UK-240455 to male rats, UK-240455 exhibits a clearance of 12 mL/min/kg and a volume of distribution of 0.4 L/kg. The plasma concentration of UK-240455 shows a decrease with an apparent half-life of 0.4 h. The analysis of urine (0 to 24 h) reveals that 57% of the administered dose is excreted unchanged. Thus, the urine clearance rate of UK-240455 in rats amounts to 7 mL/min/kg. Upon oral administration to male rats, the apparent elimination half-life of UK-240455 from plasma was observed to be 1.6 hours.[1]